Retrospectively seroprevalence study on anti-HEV-IgG antibody in patients with chronic hepatitis or liver cirrhosis in a Chinese teaching hospital

2018 ◽  
Vol 91 (3) ◽  
pp. 437-443 ◽  
Author(s):  
Hongying Yang ◽  
Jianguo Wu ◽  
Yuan Yuan ◽  
Wenxiang Huang ◽  
Bei Jia
2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Baba Sulemana Mohammed ◽  
Matthew Aidoo

The diverse influence of liver function on drug disposition can lead health-care practitioners to inappropriate drug selection, inappropriate drug dosing, or some level of therapeutic negativism. The aim of this study was to assess how drug prescribing in patients with liver cirrhosis at the Tamale Teaching Hospital comply with recommendations of pharmacotherapy and safety guidelines. A prospective cross-sectional study was conducted from February to July, 2019, at the medical ward of the Tamale Teaching Hospital. A total of 152 liver cirrhotic patients were included in this study. Common etiologies for liver cirrhosis were chronic hepatitis B 80 (52.6%) and chronic hepatitis C 30 (19.7%); about 12.5% of etiologies were unknown. Of the 1842 prescription issued, 69% (1270/1842) were compliant. Of the 572 noncompliant prescriptions, about 32% (183/572) were due to pharmacotherapy and 68% (389/572) due to safety guideline recommendations. There was a substantial number (31%) of prescription noncompliance with recommendations for pharmacotherapy and safety guidelines in liver cirrhotic patients at the tertiary hospital in northern Ghana. Prescribers need to be conscious of the role of the liver in drug elimination and prescribe as recommended by guidelines.


1968 ◽  
Vol 07 (04) ◽  
pp. 371-387
Author(s):  
T. Spârchez ◽  
B. Gheorghescu ◽  
Gh. Jovin ◽  
Elena Merculiev

SummaryWe have studied the kinetiks of vitamin B12 and especially the liver compartment, in 28 normals and 76 patients with chronic hepatitis and liver cirrhosis.The study was carried out by means of vitamin B12 58Co, administered per os (alone or followed by “flushing dosis”), vitamin B12 57Co administered intravenously and by double tracer technique.Our results indicate the Pertubation of intrahepatic storage compartment of radiocobalamine, in patients with chronic hepatitis and especially in patients with active hepatitis and in cirrhotics.This deficiency can be explained probably, by an alteration of the transport to the liver of the absorbed vitamin B12, by an inadequate chemical forme, by hepatic enzymatic disturbances or by excessive handling and storage in extrahepatic compartment.


Author(s):  
Rehab Badawi ◽  
Shaimaa Soliman ◽  
Lobna Aboali ◽  
Mahmoud Elkadeem ◽  
Asem Elfert ◽  
...  

Background & Aims: This study aimed to assess the changes in platelet counts of patients with liver cirrhosis due to chronic HCV, who achieved sustained virological response (SVR) after taking direct acting antivirals (DAAs) in a large cohort study in Egypt. Methods: This multicenter observational retrospective study was carried out on 2500 chronic hepatitis C virus (HCV) infected patients who achieved (SVR) after treatment with direct acting antiviral drugs (DAA). HCV infection was confirmed by positive PCR for HCV RNA infection. SVR was defined as a negative PCR test for HCV-RNA 12 weeks after completion of DAA therapy. Platelets count was measured before therapy, during therapy, at the end of treatment, and 12 weeks after the end of the treatment. Results: There were 2186 patients enrolled in the study; 1866 (85.4%) were treatment naïve. There were 1006 (46%) males and 1180 (54%) females. Mean age was 50.82± 11.66 years, 2142 (98 %.0) patients achieved SVR, 2118 (96.9%) patients had Child -Pugh class A cirrhosis, and 68 (3.1%) had Child -Pugh class B liver cirrhosis. A significant increase of the platelets count was detected at the end of treatment in comparison to the pretreatment levels (P<0.001), and after achieving SVR (P <0.001) when compared to the pretreatment values. Conclusion: Improvement of platelets count occurs after HCV therapy with DAAS in patients with liver cirrhosis. These results suggested that HCV eradication may have a role in improvement of platelet count.


2016 ◽  
Vol 12 (1) ◽  
pp. 405-409 ◽  
Author(s):  
HAI-PENG ZHU ◽  
YU-RONG GU ◽  
GENG-LIN ZHANG ◽  
YU-JIE SU ◽  
KE WANG ◽  
...  

2000 ◽  
Vol 126 (6) ◽  
pp. 345-351 ◽  
Author(s):  
Melchiorre Cervello ◽  
Lucrezia Virruso ◽  
Giuseppe Lipani ◽  
Lydia Giannitrapani ◽  
Maurizio Soresi ◽  
...  

2015 ◽  
Vol 6 ◽  
Author(s):  
Yaowen Chang ◽  
Guangxin Luan ◽  
Ying Xu ◽  
Yanhong Wang ◽  
Min Shen ◽  
...  

2014 ◽  
Vol 143 (2) ◽  
pp. 376-384 ◽  
Author(s):  
Y. LIU ◽  
L.-G. WAN ◽  
Q. DENG ◽  
X.-W. CAO ◽  
Y. YU ◽  
...  

SUMMARYA total of 180 non-duplicate carbapenem-resistant Klebsiella pneumoniae isolates were recovered from patients hospitalized between December 2010 and January 2012 at a Chinese hospital. Eight KPC-2, four NDM-1, one VIM-2, and five KPC-2 plus IMP-4 producers were identified and all were multidrug resistant due to the presence of other resistance determinants, including extended-spectrum β-lactamases (CTX-M-15, SHV-12), 16S rRNA methylases (armA, rmtB) and plasmid-mediated quinolone-resistance determinants (qnrA, B, S, aac(6′)-Ib-cr). Nine K. pneumoniae clones (Kpn-A1/ST395, Kpn-A3/ST11, Kpn-A2/ST134, Kpn-B/ST263, Kpn-C/ST37, Kpn-D/ST39, Kpn-E/ST1151, Kpn-F/ST890, Kpn-G/ST1153) were identified. blaKPC-2 was located on transferable ~65 kb IncL/M (ST395, ST11, ST134, ST39) and ~100 kb IncA/C (ST37, ST1153, ST890) plasmids, respectively. On the other hand, blaNDM-1 was associated with a ~70 kb IncA/C plasmid (ST263). However, non-typable plasmids of ~40 kb containing blaVIM-2 were detected in the ST1151 clone. This work reports the first co-occurrence of four diverse types of carbapenemase of K. pneumoniae clones from a single hospital in China. IncA/C, IncL/M, and other successful plasmids may be important for the dissemination of carbapenemases, producing a complex epidemiological picture.


Sign in / Sign up

Export Citation Format

Share Document